Page 58 - Read Online

Armstrong et al. Hepatoma Res 2021;7:18 I http://dx.doi.org/10.20517/2394-5079.2020.118 Page 11 of 12

35. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 2015;125:3335-7.
36. Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 2011;54:830-4.
37. Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future
directions. Hepatology 2014;60:1776-82.
38. Hong YP, Li ZD, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol
2015;7:980-92.
39. Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene 2020;39:3620-37.
40. Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2019;25:2977-89.
41. Kudo M. Pembrolizumab for the Treatment of Hepatocellular Carcinoma. Liver Cancer 2019;8:143-54.
42. Xu W, Liu K, Chen M, et al. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. Ther Adv Med Oncol
2019;11:1758835919862692.
43. Melero I, Sangro B, Riezu-Boj JI, et al. Abstract 4387: Antiviral and antitumoral effects of the anti-CTLA4 agent tremelimumab in
patients with hepatocellular carcinoma (HCC) and chronic hepatitis C virus (HCV) infection: Results from a phase II clinical trial. Cancer
Research 2012;72:4387.
44. Sangro B, Gomez-Martin C, de la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular
carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
45. El-khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label,
non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
46. Zhu AX, Knox JJ, Kudo M, et al. KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced
hepatocellular carcinoma. J Clin Oncol 2017;35:TPS504.
47. Finn RS, Ryoo BY, Merle P, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC)
for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2019;37:4004.
48. Yau T, Park J, Finn R, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as
first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019;30:v874-5.
49. Lee MS, Ryoo B, Hsu C, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an
open-label, multicentre, phase 1b study. The Lancet Oncology 2020;21:808-20.
50. Zhu AX, Finn RS, Ikeda M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular
carcinoma (uHCC). J Clin Oncol 2020;38:4519.
51. Jiao SC, Bai L, Dong J, et al. Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced
hepatocellular carcinoma (HCC). J Clin Oncol 2020;38:4592.
52. Pal SK, Vaishampayan UN, Castellano DE, et al. Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in
combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC). J
Clin Oncol 2019;37:TPS683-TPS683.
53. Kelley RK, W Oliver J, Hazra S, et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced
hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol 2020;16:1525-36.
54. Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma
Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020:e204564.
55. Kelley RK, Sangro B, Harris WP, et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination
with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC). J Clin Oncol 2020;38:4508-4508.
56. Abou-Alfa GK, Chan SL, Furuse J, et al. A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line
treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J Clin Oncol 2018;36:TPS4144-TPS4144.
57. Benson AB 3rd, D’Angelica MI, Abbott DE, et al. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr
Canc Netw 2017;15:563-73.
58. FDA. FDA expands approved use of Stivarga to treat liver cancer. Available from: https://www.fda.gov/news-events/press-
announcements/fda-expands-approved-use-stivarga-treat-liver-cancer 2017;Content Current as of: 04/27/2017. [Last accessed on 16 Dec
2020]
59. FDA. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. Available from: https://www.fda.gov/
drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib 2017;Content
current as of: 09/25/2017. [Last accessed on 16 Dec 2020]
60. FDA. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. Available from: https://www.fda.gov/drugs/fda-
grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma 2018;Content current as of: 12/14/2018. [Last accessed on 16 Dec
2020]
61. FDA. FDA approves lenvatinib for unresectable hepatocellular carcinoma. Available from: https://www.fda.gov/drugs/resources-
information-approved-drugs/fda-approves-lenvatinib-unresectable-hepatocellular-carcinoma 2018;Content current as of: 08/16/2018. [Last
accessed on 16 Dec 2020]
62. FDA. FDA approves ramucirumab for hepatocellular carcinoma. Available from: https://www.fda.gov/drugs/resources-information-
approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma 2019;Content current as of: 05/10/2019. [Last accessed on 16 Dec
2020]
63. FDA. FDA approves cabozantinib for hepatocellular carcinoma. Available from: https://www.fda.gov/drugs/fda-approves-cabozantinib-
hepatocellular-carcinoma 2019;Content current as of: 03/12/2019. [Last accessed on 16 Dec 2020]